Columbia University is in line for an exit as cancer drug developer Vor files for its initial public offering.

Novo and GV participated in a round that lifted the Harvard, Broad Institute and Penn-linked heart disease drug developer's overall funding to more than $215m.

The immunotherapy developer plans to go public in the US having raised $565m since being formed to develop assets of a defunct Oxford spinout.

The Institute for Neurophysiopathology spinout has completed a series D round.

University of Washington spinout AltPep will use the money to advance work on its lead asset that targets Alzheimer’s disease.

PureTech Health, Johnson & Johnson and Novartis are in line for exits after the cancer drug developer filed for its initial public offering.

The immunotherapy developer plans to go public in the United States having raised $565m from investors including Eli Lilly and WuXi AppTec.

Cambrian Biopharma is the largest investor in cancer immunotherapy developer Sensei Biotherapeutics, which has filed to raise up to $100m.

Novo and existing backer GV participated in a round that lifted the heart disease drug developer's overall funding to more than $215m.

University of Washington spinout AltPep will use the proceeds from the Alexandria Venture Investments-backed round to advance a lead asset targeting Alzheimer’s disease.